Reuters logo
FDA panel does not recommend Taltorvic
March 20, 2012 / 8:32 PM / 6 years ago

FDA panel does not recommend Taltorvic

WASHINGTON, March 20 (Reuters) - A Food and Drug Administration panel on Tuesday chose not to recommend a drug developed by Merck & Co Inc and Ariad Pharmaceuticals Inc for maintenance treatmement for soft-tissue and bone sarcoma.

The advisory committee of outside experts voted 13-1 to conclude that the short-term benefits offered by the drug Taltorvic did not outweigh the risks of adverse reactions and a lack of evidence of improved overall survival.

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below